Biomedical subjects
A Manzoli
Publications and source records attributed to A Manzoli.
[Weakening of anti-A and anti-B with karyotype abnormality associated with multiple myeloma].
Explore the source record for details and available documents.
Apoptosis in recent myocardial infarction.
PURPOSE: Apoptosis is considered a common pathological feature in acute myocardial infarction (MI) and heart failure; however its role in the later phases post MI has not been characterized. The goal of our study was to investigate by pathological examination human hearts at 20 to 30 days post MI and identify signs of ongoing cell apoptosis. MATERIALS AND METHODS: Two hearts were collected at autopsy from patients who died 20 to 30 days from the onset of MI (Cases 1 and 2). Gross anatomy and light microscopy examination of the hearts was performed to define the infarcted area and the infarct-related artery. The in situ end-labeling of DNA fragmentation (TUNEL) was performed to identify apoptotic cells and the apoptotic rate (AR) was calculated. RESULTS: There were no signs of acute necrosis in any of the specimens examined. A high number of myocardiocyte were positive at TUNEL examination in specimens obtained at sites of infarction, mean AR = 44%, but not in specimens derived from the same patients at regions remote from the MI, AR = 0. CONCLUSIONS: High grade apoptosis is present at sites of infarction and not in regions remote from the infarcted area in the later phases post MI. These data support persistent myocardiocyte loss and identify a possible explanation of progressive left ventricular dysfunction in the subacute phases of MI.
[Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
Glycoprotein IIb-IIIa receptor inhibitors are the newest anti-platelets drugs currently used in patients with coronary artery disease. We examined mechanisms of their action and different pharmacokinetic and pharmacodynamic characteristics of the four glycoprotein IIb-IIIa antagonists evaluated in randomized, controlled and multicenter trials. We reviewed results of these trials in the settings of percutaneous revascularizations procedures or unstable coronary syndromes. Platelet glycoprotein IIb-IIIa receptor inhibitors reduced incidence of cardiac death and myocardial infarction during the short- and midterm, and benefit was greater in: a) patients undergoing coronary angioplasty with or without stent implantation, particularly in the presence of unstable angina, diabetes or complex and diffuse coronary artery disease; b) as a direct therapy of unstable coronary syndromes, particularly in patients with refractory angina, diabetes and elevated Troponin; more recently they have been used as adjuvant therapy in acute myocardial infarction. Infusion of these drugs was not associated with higher rates of major bleedings.
[Statins: from hypocholesteremic drugs to antiatherogenic agents].
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) are widely used for the treatment of hypercholesterolemia. They reduce LDL levels more than other lipid-lowering drugs. Moreover, they are effective in raising HDL and even in reducing triglyceride levels. Statins have an excellent tolerability and safety. Clinical trials in patients with and without ischemic heart disease and with and without high cholesterol levels have demonstrated that statins significantly reduce the relative risk of major coronary events and of total mortality. Other mechanisms independent of LDL lowering may play an important role in the clinical benefits conferred by these drugs and may broaden their therapeutic indications from lipid-lowering to antiatherogenic agents.
[The incidence of irregular blood group antibodies in the practice of a transfusion center].
Explore the source record for details and available documents.